|The GRK3 n/a (Catalog #MBS628318) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The GRK3, CT (G Protein Coupled Receptor Kinase 3, Beta-adrenergic Receptor Kinase 2, ADRBK2, Beta-ARK-2, BARK2) reacts with Human, Mouse and may cross-react with other species as described in the data sheet. MyBioSource\'s GRK3 can be used in a range of immunoassay formats including, but not limited to, ELISA (EL/EIA), Western Blot (WB).
Suitable for use in ELISA and Western Blot.
Dilution: ELISA: 1:1,000
Western Blot: 1:100-1:500. Researchers should empirically determine the suitability of the GRK3 n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
The beta-adrenergic receptor kinase specifically phosphorylates the agonist-occupied form of the beta-adrenergic and related G protein-coupled receptors. Overall, the ADRBK2 enzyme, also known as GRK3, has 85% amino acid similarity with ADRBK1, with the protein kinase catalytic domain having 95% similarity. The ADRBK2 mRNA is approximately 8 kilobases with a distribution similar to that of ADRBK1. These data suggest the existence of a family of receptor kinases which may serve broadly to regulate receptor function.
Immunogen: Synthetic peptide selected from the C-term region of human GRK3 (KLH). In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing GRK3 are readily searchable from our website. Different antibodies against the same target such as GRK3 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.